Chimeric antigen receptor T cells demonstrate efficacy in B-cell malignancies, leading to US
Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and …

Background In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19
chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory …

In October 2017, the FDA granted regular approval to axicabtagene ciloleucel, a CD19-
directed chimeric antigen receptor (CAR) T-cell therapy, for treatment of adult patients with …

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapies can be effective for diffuse large
B-cell lymphoma (DLBCL), a cancer with limited treatment options and poor outcomes …

Introduction Axi-cel is an autologous anti-CD19 CAR T-cell therapy approved by the US FDA
10/18/2017, for the treatment of adults with relapsed or refractory (r/r) large B-cell lymphoma …

Background Diffuse large B-cell lymphoma (DLBCL) is the most prevalent subtype of non-
Hodgkin lymphoma. Although outcomes to frontline therapy are encouraging, patients who …

Chimeric antigen receptor (CAR)‐T cell therapies have improved the outcome for many
patients with relapsed or refractory aggressive B‐cell lymphomas. In 2017, axicabtagene …

Importance Axicabtagene ciloleucel, an anti-CD19-CD28-CD3ζ chimeric antigen receptor T-
cell therapy, was the first US Food and Drug Administration–approved, genetically …

PURPOSE Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric
antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell …

Background Patients with diffuse large B-cell lymphoma that is refractory to primary and
second-line therapies or that has relapsed after stem-cell transplantation have a poor …